Cure My Disease

Don't miss your cure!

 Log in / Sign up

Monthly HIV prevention pill tested in women – study halted early

NCT ID NCT04644029

Terminated Prevention Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new monthly pill (islatravir) to see if it could prevent HIV infection better than a daily pill in 730 women at high risk. The trial was stopped early, so results are limited. The goal was to offer a more convenient prevention option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-I are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-I HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROPHYLAXIS

Contacts and locations

Locations

  • Aurum Institute - Rustenburg ( Site 0022)

    Rustenburg, North West, 0299, South Africa

  • Aurum Institute Klerksdorp CRS ( Site 0029)

    Klerksdorp, North West, 2571, South Africa

  • Bronx Prevention Center ICAP ( Site 0062)

    The Bronx, New York, 10451, United States

  • Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0020)

    Johannesburg, Gauteng, 2092, South Africa

  • KC CARE Health Center-Clinical Trials ( Site 0059)

    Kansas City, Missouri, 64111, United States

  • MU-JHU Care Limited-Clinic ( Site 0041)

    Kampala, 10216, Uganda

  • Madibeng Centre for Research ( Site 0019)

    Brits, North West, 0250, South Africa

  • Maternal Adolescent and Child Health Research (MatCH) ( Site 0025)

    Durban, KwaZulu-Natal, 4001, South Africa

  • MedStar Health Research Institute (MedStar Physician Based R-MedStar Washington Hospital Center ( Si

    Washington D.C., District of Columbia, 20010, United States

  • Orlando Immunology Center ( Site 0068)

    Orlando, Florida, 32803, United States

  • Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0023)

    Johannesburg, Gauteng, 1864, South Africa

  • Ponce De Leon Center Grady Health ( Site 0066)

    Atlanta, Georgia, 30308, United States

  • Prism Health North Texas, Oak Cliff Health Center ( Site 0070)

    Dallas, Texas, 75208, United States

  • Prisma Health Richland Hospital-Clinical Research Unit ( Site 0069)

    Columbia, South Carolina, 29203, United States

  • Qhakaza Mbokodo Research Clinic ( Site 0017)

    Ladysmith, KwaZulu-Natal, 3370, South Africa

  • Rutgers New Jersey Medical School-Clinical Research Center ( Site 0071)

    Newark, New Jersey, 07103, United States

  • SA Medical Research Council - Chatsworth Clinical Research Site ( Site 0030)

    Chatsworth, KwaZulu-Natal, 4092, South Africa

  • Setshaba Research Centre ( Site 0016)

    Pretoria, Gauteng, 0152, South Africa

  • The University of Mississippi Medical Center ( Site 0065)

    Jackson, Mississippi, 39216, United States

  • The University of North Carolina at Chapel Hill-Medicine ( Site 0056)

    Chapel Hill, North Carolina, 27599, United States

  • University of Alabama at Birmingham-UAB Sexual Health Research Clinic (SHRC) ( Site 0064)

    Birmingham, Alabama, 35205, United States

  • University of Miami Miller School of Medicine-Infectious Disease ( Site 0076)

    Miami, Florida, 33136, United States

  • West Virginia University-Department of Medicine ( Site 0061)

    Morgantown, West Virginia, 26506, United States

  • Wits Reproductive Health and HIV Institute (WRHI)-Wits RHI Ward 21 Clinical Research site ( Site 002

    Johannesburg, Gauteng, 2000, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.